SCAPA GROUP PLC ANNUAL REPORT AND ACCOUNTS 2017 FULFILLING   POTENTIAL SCAPA GROUP PLC ANNUAL REPORT AND ACCOUNTS 2017 SCAPA GROUP IS A GLOBAL  SUPPLIER OF BONDING SOLUTIONS  AND MANUFACTURER OF  ADHESIVE‑BASED PRODUCTS  FOR THE HEALTHCARE AND  INDUSTRIAL MARKETS. At Scapa, we base our approach on a  deep understanding of our core markets. This understanding allows us to anticipate  tomorrow’s customer needs and to enable  our customers to succeed in dynamic markets. STRATEGIC REPORT 1 Financial Highlights 2 Our Business at a Glance 4 Chairman’s Letter 6 Chief Executive’s Strategic Review 10 Key Performance Indicators  12 Risk Management  15 Principal Risks and Uncertainties 19 Viability Statement 20 Business Review: Healthcare  24 Business Review: Industrial 28 Finance Director’s Review 32 Sustainability Report  CORPORATE GOVERNANCE 38 Chairman’s Introduction to   Corporate Governance 40 Board of Directors  42 Corporate Governance 47 Report of the Audit and   Risk Committee 51 Report of the Nominations Committee 53 Report of the Remuneration Committee 56 Directors’ Remuneration Policy 61 Directors’ Annual Remuneration Report 68 Directors’ Report FINANCIAL STATEMENTS 70 Directors’ Responsibilities 71 Independent Auditor’s Report 79 Consolidated Income Statement 79 Consolidated Statement   of Comprehensive Income 80 Consolidated Balance Sheet 81 Consolidated Statement of Changes in Equity 82 Consolidated Cash Flow Statement 83 Group Accounting Policies 92 Notes on the Accounts 123 Five Year Summaries 124 Parent Company Financial Statements 125 Company Balance Sheet 126 Company Statement of Changes in Equity 127 Statement of Accounting Policies 129 Notes on the Accounts  COMPANY INFORMATION 138 Company Information Visit our websites:    29.2 21.3 18.6 15.5 13.7 TRADING PROFIT* £29.2m 2013 2014 2015 2016 2017 279.6 246.7 236.0 226.1 208.8 2013 2014 2015 2016 2017 GROUP REVENUE £279.6m ADJUSTED EARNINGS PER SHARE**  14.8p 14.8 10.6 9.1 7.2 6.0 2013 2014 2015 2016 2017 21.8 9.8 13.7 11.2 9.6 PROFIT BEFORE TAX £21.8m 2013 2014 2015 2016 2017 FINANCIAL HIGHLIGHTS • Scapa achieved significant goals this  year – Healthcare exceeded £100m in  sales, Industrial achieved double-digit  margins, and the Company achieved  £500m market capitalisation • Revenue, trading profit and margins  grew for the seventh consecutive  year, showing the benefit of a  consistent and well executed strategy • Revenue increased to £279.6m,  helped by currency tailwinds and the  acquisition of EuroMed • Trading profit increased to £29.2m  with both businesses contributing well • Margins increased to 10.4% as the  Industrial ROCE strategy continues  to deliver  • This strong performance results in  an adjusted EPS increase of 39.6%,  supporting an increase in the  dividend to 2.0p from 1.75p * Operating profit before amortisation of intangible assets, exceptional items and pension administration costs ** Adjusted for exceptional items, amortisation of intangible assets, pension administration costs, non-cash interest, and the tax thereon STRATEGIC REPORT SCAPA GROUP PLC ANNUAL REPORT AND ACCOUNTS 2017 1 £116.4m (2016: £103.4m) £14.4m (2016: £14.0m) £148.8m (2016: £129.3m) OUR BUSINESS AT A GLANCE We are made up of two distinct and  separate businesses: Healthcare and  Industrial, each with its own focus and  strategy. With a global reach in each  of the markets in which we participate,  we are focused on sustainable growth  and innovation, improving the solutions for  our customers by applying our knowledge  and expertise in advanced material  technology and process solutions. A trusted strategic  outsource partner to  the global healthcare  industry, delivering   turn-key solutions  and support for our  customers through  all stages of the   product life cycle. The Industrial business  operates across a  wide range of markets  and geographies. It manufactures and   delivers an extensive  portfolio of adhesive  bonding solutions and  applications to a global  customer base. REVENUE BY GEOGRAPHY  Europe    Asia   North America HEALTHCARE INDUSTRIAL  Turn to page 20  Turn to page 24 REVENUE £108.7m (2016: £93.3m) REVENUE £170.9m (2016: £153.4m) 2 SECTION TITLE: PAGE REF 2 STRATEGIC REPORT   TRADING PROFIT* £16.6m (2016: £14.0m) MARGIN  15.3% (2016: 15.0%) TRADING PROFIT* £17.8m (2016: £10.7m) MARGIN  10.4% (2016: 7.0%) GLOBAL LOCATIONS HIGHLIGHTS • EuroMed now fully integrated and  contributing well to H2 performance • Three-year agreements signed with  major customers in Consumer Wellness  and Medical Devices • Increased sales of turn-key products  contributing to margin improvement • New products launched for acne  treatment, insulin delivery system  and wound care • Positive outlook for FY18 with good   sales pipeline HIGHLIGHTS • Double-digit margins achieved – focus  now to increase margins further to  industry average mid-teens • Rorschach closure executed well  and £1m of benefits delivered in H2  as promised • Good progress on operational efficiency  and supply chain costs • Growth in sales in key segments – good  results for innovative products specified  into Auto and Cable customers, and  improvement in the construction section  where we exceeded GDP growth MARKET SNAPSHOT The market sectors we focus on today  are Advanced Wound Care, Consumer  Wellness and Medical Devices, including  the rapidly growing Wearable Medical  Device Fixation market. With our global  footprint we can service and support all  customer needs wherever they may be..